TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06178367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight hyaluronic acid
Description: Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High molecular weight hyaluronic acid
Description: Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
Study: NCT04915508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: Receive hormonal therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05185401

Intervention type: OTHER
Intervention: Observational study
Description: Retrospective data-analysis
Study: NCT06302465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide
Description: Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin、cisplatin、methotrexate、ifosfamide
Description: doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
Study: NCT05461599

Intervention type: DEVICE
Group type: OTHER
Intervention: SparkRx Mobile App
Description: The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
Study: NCT05048680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia and/or Exercise
Description: Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia and/or Exercise
Description: Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia and/or Exercise
Description: Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia and/or Exercise
Description: Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
Study: NCT05307536

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous BMMNCs transplantation and educational intervention
Description: Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model
Study: NCT05464472

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
Study: NCT05840978

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Oral capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Oral capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT05569564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge splitting followed by ossedensificaion
Description: Ridge splitting followed by ossedensificaion with osseodensifying burs.
Study: NCT04762082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 10 MG
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
Study: NCT05307536

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Educational intervention: 6 months based on the Early Start Denver Model
Study: NCT05569564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseodensification
Description: Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification
Description: Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
Study: NCT05904353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulant nurse-assisted administration of zoledronic acid
Description: Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
Study: NCT04762082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
Study: NCT06266845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person Escape Room
Description: The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person Escape Room
Description: The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person Escape Room
Description: The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Escape-Room
Description: The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
Study: NCT05240170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS
Description: The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWL
Description: Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
Study: NCT06266845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Escape-Room
Description: The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Escape-Room
Description: The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
Study: NCT06467773

Intervention type: RADIATION
Intervention: Radiation: PET-MRI with [18F]-DPA-714
Description: Radiation: PET-MRI with \[18F\]-DPA-714

Intervention type: RADIATION
Intervention: Radiation: PET-MRI with [18F]-DPA-714
Description: Radiation: PET-MRI with \[18F\]-DPA-714

Intervention type: RADIATION
Intervention: Radiation: PET-MRI with [18F]-DPA-714
Description: Radiation: PET-MRI with \[18F\]-DPA-714
Study: NCT04801797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion
Study: NCT04735315

Intervention type: OTHER
Intervention: Preterm birth
Description: The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)

Intervention type: OTHER
Intervention: Preterm birth
Description: The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
Study: NCT05412043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance therapy
Description: The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability
Description: The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability
Description: The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability
Description: The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
Study: NCT06512610

Intervention type: OTHER
Intervention: Middle Eastern or North Coast of Africa patients with newly AML
Description: Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
Study: NCT04801797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin and cytarabine
Description: Intravenous infusion
Study: NCT05309681

Intervention type: OTHER
Intervention: Epworth's sleepiness scale; unstimulated saliva sample
Description: Unstimulated saliva sample; Epworth's sleepiness scale

Intervention type: OTHER
Intervention: Epworth's sleepiness scale; unstimulated saliva sample
Description: Unstimulated saliva sample; Epworth's sleepiness scale
Study: NCT05844202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveavax-v1.2
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveavax-v1.2
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveavax-v1.2
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveavax-v1.2
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Janssen Ad26.COV2.S
Description: COVID-19 vaccine by Janssen / Johnson \& Johnson
Study: NCT05679349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo online shared decision making training and distance learning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Undergo electronic health record review

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo online shared decision making training and distance learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo shared decision making counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Undergo electronic health record review
Study: NCT04578756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)
Study: NCT04801797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous infusion
Study: NCT04787211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given by intravenous administration
Study: NCT06271928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yijing Keli
Description: Once enrolled, participants will be administrated Yijing Keli
Study: NCT05186272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction program 'A'
Description: Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress reduction program 'B'
Description: Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
Study: NCT05874830

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplant or plasebo through endoscopy
Description: Colonoscopy and gastroscopy
Study: NCT06006910

Intervention type: BEHAVIORAL
Intervention: Column-based nudge in the EHR
Description: The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
Study: NCT04578756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: 1 capsule to be taken orally at approximately the same time of day (morning or evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine Flexible Dose
Description: Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
Study: NCT06307249

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: Diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: Diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: Diagnostics of patients' carriers or not of the risk allele(s)
Study: NCT06006910

Intervention type: BEHAVIORAL
Intervention: No column-based nudge in the EHR
Description: No intervention control period prior to nudge deployment.
Study: NCT06054503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prototype of sensor
Description: The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters